Feasibility of a clinical trial to assess the effect of dietary calciumv.supplemental calcium on vascular and bone markers in healthy postmenopausal women
- Resource Type
- Authors
- Angel M. Ong; Stella S. Daskalopoulou; Jessica Gorgui; Hope A. Weiler; Rouba Haddad; Suzanne N Morin; David Goltzman; Michelle Wall
- Source
- British Journal of Nutrition. 116:104-114
- Subject
- medicine.medical_specialty
Medicine (miscellaneous)
Parathyroid hormone
chemistry.chemical_element
030204 cardiovascular system & hematology
Calcium
Gastroenterology
Bone and Bones
Calcium Carbonate
law.invention
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
medicine
Humans
030212 general & internal medicine
Pulse wave velocity
Aged
Nutrition and Dietetics
Postmenopausal women
business.industry
Bone markers
Middle Aged
medicine.disease
Calcium, Dietary
Postmenopause
Clinical trial
Endocrinology
chemistry
Cardiovascular Diseases
Arterial stiffness
Female
business
Biomarkers
- Language
- ISSN
- 1475-2662
0007-1145
Whether supplemental Ca has similar effects to dietary Ca on vascular and bone markers is unknown. The present trial investigated the feasibility of applying dietary and supplemental interventions in a randomised-controlled trial (RCT) aiming to estimate the effect of supplemental Ca as compared with dietary Ca on vascular and bone markers in postmenopausal women. In total, thirteen participants were randomised to a Ca supplement group (CaSuppl) (750 mg Ca from CaCO3+450 mg Ca from food+20 µg vitamin D supplement) or a Ca diet group (CaDiet) (1200 mg Ca from food+10 µg vitamin D supplement). Participants were instructed on Ca consumption targets at baseline. Monthly telephone follow-ups were conducted to assess adherence to interventions (±20 % of target total Ca) using the multiple-pass 24-h recall method and reported pill count. Measurements of arterial stiffness, peripheral blood pressure and body composition were performed at baseline and after 6 and 12 months in all participants who completed the trial (n9). Blood and serum biomarkers were measured at baseline and at 12 months. Both groups were compliant to trial interventions (±20 % of target total Ca intake; pill count ≥80 %). CaSuppl participants maintained a significantly lower average dietary Ca intake compared with CaDiet participants throughout the trial (453 (sd187) mg/dv.1241 (sd319) mg/d;P